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1 Drug description 
Generic/Brand name/ATC code:  
Pomalidomide, CC-4047/ Imnovid® (Europe), Pomalyst® (U.S.)/L04AX06 
Developer/Company:  
Celgene Corporation 
Description 
Pomalidomide, an analogue of thalidomide, is a new immunomodulatory 
antineoplastic agent. The mechanism of action of pomalidomide is not fully 
understood but three broad modes of action have been identified: an anti-
tumour effect (antiproliferative, pro-apoptotic), modulation of the bone 
marrow micro-environment (anti-angiogenic, anti-inflammatory) and modu-
lation of the immune system (natural killer-cells and T-cell activa-
tion/stimulation) [1]. Thus, this agent induces apoptosis and inhibits prolif-
eration of multiple myeloma (MM) cells by modulating expression of cyto-
kines that stimulate T-cells and natural killer cells or down-regulate angio-
genesis [2, 3]. Pomalidomide has also shown activity in lenalidomide and/or 
bortezomib-resistant MM cell lines [3-5]. 
Pomalidomide is available in 1 mg, 2 mg, 3 mg and 4 mg capsules for oral 
administration. The dosage is 4 mg per day taken orally on days 1–21 of re-
peated 28-day cycles until disease progression [6]. Because of the risk of ve-
nous thromboembolism (deep venous thrombosis and pulmonary embolism) 
with pomalidomide therapy, prophylactic anti-thrombotic therapy is indi-
cated.  
 
2 Indication 
Pomalidomide is indicated for patients with relapsed and refractory MM 
who have received at least two prior treatment regimens, including both 
lenalidomide and bortezomib and who have demonstrated disease progres-
sion on the last therapy.   
 
 
3 Current regulatory status 
Orphan designation was assigned to pomalidomide for the treatment of MM 
by the EMA in October 2009 [7]. On the 30th of May 2013, EMA’s Commit-
tee for Medicinal Products for Human Use (CHMP) adopted a positive opin-
ion, recommending marketing authorisation for pomalidomide and on the 
5th of August 2013 marketing authorisation was issued for pomalidomide 
 in combination with dexamethasone for the treatment of adult pa-
tients with relapsed and refractory MM who have received at least 
two prior treatment regimens, including both lenalidomide and 
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bortezomib, and have demonstrated disease progression on the last 
therapy [8]. 
 
In the U.S., pomalidomide also has orphan drug status for MM and the FDA 
granted market authorization on February 2013 for  
 
 patients with MM who have received at least two prior therapies in-
cluding lenalidomide and bortezomib and have demonstrated dis-
ease progression on or within 60 days of completion of the last ther-
apy [9].  
 
 
4 Burden of disease 
MM is an incurable malignant plasma cell disorder characterised by osteo-
lytic bone lesions, renal disease and immunodeficiency and belongs to the B-
cell type of lymphoma. MM accounts for about 10% of all haematological 
malignancies and is, after non-Hodgkin’s lymphoma (NHL), the second 
most common haematologic malignancy, with men being affected more  
often than women [10, 11]. The incidence of MM is estimated to be 4–6 per 
100,000 habitants, with a median age of 70 years at time of diagnosis [12]. 
MM is therefore often referred to as a disease of the elderly, with only about 
35% of MM patients being younger than 65 years [13, 14].  
About 20% of patients are symptom-free at time of diagnosis [15, 16]. Raised 
erythrocyte sedimentation rate, plasma viscosity, serum protein or globulin 
lead to incidental detection of MM. Clinical features of MM present at time 
of diagnosis are bone disease, impaired renal function, anaemia, hypercal-
caemia, recurrent or persistent bacterial infection and hyperviscosity [17]. 
If MM is suspected, a range of investigations and tests are indicated to con-
firm diagnosis, estimate tumour burden and prognosis and assess myeloma-
related organ impairment. Further, these tests aim to differentiate between 
patients with active and symptomatic MM that requires systemic therapy 
and monoclonal gammopathy of undetermined significance (MGUS), 
smouldering or indolent myeloma or solitary plasmocytoma, none of which 
require systemic therapy in the first instance [10, 15, 17].  
The natural history of MM is very heterogeneous. Initially, the Durie and 
Salmon system [18] was the staging system of choice until it was superseded 
by the International Staging System (ISS) for MM [19]. The ISS defines 3 
risk categories (stages I, II and III) with a corresponding median survival 
time of 62, 45 and 29 months in stages I, II and III, respectively. Biological 
parameters in particular (e.g. β2-microglobulin, C-reactive protein, lactate 
dehydrogenase and serum albumin) are of prognostic relevance and thus in-
corporated in the determination of the ISS stage [15, 17]. The ISS is valid for 
prognostic purposes, but its use to determine choice of therapy for individu-
al patients is still unproven [17]. Factors associated with poor prognosis in-
clude genetic abnormalities such as t(4;14), t(14;16) and deletion 17p 
demonstrated by fluorescence in situ hybridisation [17]. Patients presenting 
these prognostic factors are generally referred to as “high-risk” MM patients.  
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Despite advances in treatment options for MM, nearly all patients eventual-
ly relapse. Relapse is defined as development of progressive disease after 
maximal response has been achieved, whereas refractory refers to patients 
that are either unresponsive to current therapy or progress within 60 days of 
last treatment [20]. These patients usually have a poor prognosis with a me-
dian overall survival (OS) less than a year [20, 21]. 
 
5 Current treatment 
Patients with newly diagnosed MM are initially assessed for stem cell trans-
plant eligibility. Regardless of eligibility for transplantation, systemic treat-
ment options include:  
 Immunomodulatory drugs: lenalidomide, thalidomide 
 Proteasome inhibitors: bortezomib, carfilzomib (not licensed in  
Europe) 
 Corticosteroids: dexamethasone, prednisone 
 Alkylators: e.g melphalan, cyclophosphamide 
 Anthracycline: e.g. doxorubicin 
 
However, all patients eventually progress. When patients relapse, duration 
of response, prior lines of therapy, presence of high-risk disease and toxici-
ties and co-morbidities determine choice of further therapy [22]. Thus, 
either re-challenge with previous therapies or alternative treatment options 
are indicated, e.g.   
 
 bortezomib ± pegylated liposomal doxorubicin or dexamethasone 
 lenalidomide ± dexamethasone 
 thalidomide + dexamethasone 
 lenalidomide or bortezomib + cyclophosphamide + dexamethasone  
 bortezomib + thalidomide + dexamethasone  
 carfilzomib (not licensed in Europe) [23-25]. 
 
However, for heavily pre-treated patients who have relapsed and refractory 
disease (that is, progression within 60 days of their last therapy in patients 
who have previously experienced a minimal response or non-responsive dis-
ease to salvage therapy) during or after treatment with bortezomib and/or 
lenalidomide, therapeutic options are limited and enrolment into a clinical 
trial is highly encouraged [23, 26]. 
 
6 Evidence 
A literature search was conducted on the 14th of May in 4 databases (Ovid 
Medline, Embase, Cochrane Library, CRD Database). Search terms were  
“pomalidomide”, “pomalyst”, “actimid”, “cc4047”, “cc 4047”, “refractory 
multiple myelomas” and “multiple myeloma”. Overall 159 references were 
identified. In addition, the manufacturer was contacted for further evi-
dence and submitted 6 references (2 full texts, 4 abstracts). Of these, one 
reference [27] had already been identified by the systematic literature 
available treatment 
options 
therapeutic options 
after disease 
progression 
heavily pre-treated 
patients with relapsed 
and refractory MM have 
limited treatment 
options 
literature search in 4 
databases yielded 159 
hits 
 
manufacturer sub- 
mitted 6 further 
references 
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search and one was a review [1]. Thus 4 abstracts, all relating to a phase III 
study, were included.   
Overall, results of 4 studies were included in this report. For the pivotal 
CC-4047-MM-002 trial, a phase II study, FDA licensing documents [28] 
and several abstracts [29-37] were used. Results of the phase III trial have 
been published as conference abstracts [38-44], but shortly prior to publi-
cation of this report the full text was published and was therefore also in-
cluded [45]. Two further phase II studies [27, 28, 46] were included.  
Excluded were studies where patients had not been treated previously with 
both lenalidomide and bortezomib [47, 48] and results of phase I and 
phase II studies available as conference abstracts only.  
 
 
6.1 Efficacy and safety  
6.1.1 Phase III study  
Table 1: Summary of efficacy 
Study title  
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with 
relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial 
Source of 
information 
Full text [45], EMA licensing documents [49], abstracts, presentation, other [38-44] 
Study  
identifier 
NCT01311687, CC-4047-MM-003, 2010-019820-30, NIMBUS trial 
Design Multi-centre, randomised, open-label, phase III, 2:1 randomization 
Duration  Enrolment: March 2011 – August 2012 
Median follow-up: 4.2 months as of September 2012, 10.0 months as 
of March 2013 
Cut-off dates for analyses:  
Final PFS analysis and interim OS: September 2012 
Updated PFS and final OS analysis: March 2013 
Hypothesis Superiority: with 85% power to detect a 50% improvement in median PFS (HR 1.5 for 
pomalidomide plus low-dose dexamethasone vs. high-dose dexamethasone) at a two-
sided significance level of 0.05 
Funding Celgene Corporation 
Treatment 
groups 
Overall study 
population 
N = 455 
 POM + DEX 
(n=302) 
Oral pomalidomide 4 mg/day for 21 days and dexamethasone 40 
mg (for patients ≤ 75 years) or 20 mg (for patients >75 years) on 
days 1, 8, 15 and 22 of each 28-day cycle until disease progression 
or unacceptable toxicity 
HiDEX 
(n=153) 
Oral high-dose dexamethasone 40 mg (for patients ≤ 75 years) or 
20 mg (for patients >75 years) on days 1–4, 9– 12, and 17–20 of a 
28-day cycle until disease progression or unacceptable toxicity 
 
 
results of 3 phase II 
studies and 1 phase III 
study included 
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Endpoints 
and 
definitions 
Progression-free 
survival 
(primary outcome) 
PFS Number of months between randomization and disease 
progression in accordance with International Myeloma 
Working Group criteria (IMWG)) or death  
Overall survival OS NA 
Overall response 
rate 
ORR Proportion of patients achieving at least partial response 
according to IMWG criteria or EBMT criteria for minor 
response only based on investigator assessment 
Duration of 
response  
DOR In patients with at least partial response 
Time to 
progression 
TTP Time from randomization to the first documented 
progression confirmed by the Independent Response 
Adjudication Committee 
Quality of life QoL Change scores and minimal important differences were 
calculated as meaningful change from baseline through C5 
(1 standard error of measurement) for 5 clinically relevant 
EORTC QLQ-C30 domains (Global Health Status, Physical 
Functioning, Fatigue, Emotional Functioning, and Pain)  
Results and analysis 
Analysis  
description 
Intention-to-treat 
PFS was estimated with the Kaplan- Meier product-limit method and a log-rank test 
(stratified by the three randomisation stratification variables) was used as the primary 
analytic method to compare survivorship functions between treatment groups. 
Analysis  
population 
Inclusion  Documented diagnosis of multiple myeloma and have measurable 
disease 
 Prior treatment with ≥ 2 treatment lines of anti-myeloma therapy 
 Either refractory or relapsed and refractory disease defined as 
documented disease progression during or within 60 days of com-
pleting their last myeloma therapy 
 At least 2 consecutive cycles of prior treatment that included le-
nalidomide and bortezomib 
 Failed treatment with both lenalidomide and bortezomib in one of 
the following ways: 1) Documented progressive disease on or 
within 60 days of completing treatment with lenalidomide and/or 
bortezomib, or 2) In case of prior response (≥ PR) to lenalidomide 
or bortezomib, subjects must have relapsed within 6 months after 
stopping treatment with lenalidomide and/or bortezomib-
containing regimens, or 3) Subjects who have not had a ≥ minimal 
response (MR) and have developed intolerance/toxicity after a 
minimum of two cycles of lenalidomide- and/or bortezomib-
containing regimen 
 Adequate prior alkylator therapy 
 ECOG PS score of 0 - 2 
Analysis 
population 
Exclusion  Previous therapy with pomalidomide 
 Hypersensitivity to thalidomide, lenalidomide, or  
dexamethasone 
 Resistance to high-dose dexamethasone used in the last line of 
therapy 
 Peripheral neuropathy ≥ Grade 2 
 Subjects who received an allogeneic bone marrow or allo-geneic 
peripheral blood stem cell transplant 
 Subjects who are planning for or are eligible for stem cell trans-
plant 
Horizon Scanning in Oncology 
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Analysis 
population 
Characteristics  POM + DEX HiDEX 
 Median age, yrs 
(range) 
>65, % 
>75, % 
64 (35 – 84) 
 
45 
8 
65 (35 – 87) 
 
47 
8 
ECOG PS, % 
0 –1 
2 – 3 
 
82 
17 
 
80 
18 
Median number 
of prior 
therapies, n 
(range) 
More than 2, % 
5 (2 – 14) 
 
 
94 
5 (2 – 17) 
 
 
95 
Previous 
treatments, % 
  
Thalidomide 57 61 
Lenalidomide 100 100 
Bortezomib 100 100 
Refractory to, 
%  
lenalidomide 
 
95 
 
92 
bortezomib 79 79 
lenalidomide 
and bortezomib 
75 74 
Median time 
from diagnosis, 
yrs 
5.3 6.1 
Baseline MM 
Stage, % 
I–II 
III 
 
65 
31 
 
61 
35 
Descriptive 
statistics 
and 
estimated 
variability 
Treatment group POM + DEX  HiDEX  
Number of subjects N = 302 N = 153 
Median PFS, months (95%CI) 
September 2012  
Independent Review 
Adjudication Committee 
Investigator assessed 
 
 
3.6 (3.0 – 4.6)1 
 
3.8 (3.4 – 4.6) 
 
 
1.8 (1.6 – 2.1) 1 
 
1.9 (1.9 – 2.1) 
March 2013  
Investigator assessed 
 
4.0 (3.6 – 4.7) 
 
1.9 (1.9 – 2.2) 
Median OS, months (95%CI) 
September 2012 
 
11.9 (10.4 – 15.5) 
 
7.8 (6.4 - 9.2) 
March 2013 12.7 (10.4 – 15-5) 8.1 (6.9 – 10.8) 
ORR, n (%)2  - March 2013 
≥VGPR 
sCR/CR 
PR 
95 (31) 
14 (5) 
3 (1) 
78 (26) 
15 (10) 
1 (<1) 
0 (0) 
14 (9) 
                                                             
1 Data were presented in weeks and were converted to months by multiplication by 7 and division by 30.5.  
2 Response based investigator assessment and IMWG criteria, except for MR (based on EBMT criteria) 
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Descriptive 
statistics 
and 
estimated 
variability 
Median DOR, months (95%CI)   
September 2012 
March 2013 
 
2.8 (NA) 
7.0 (6.0 – 9.0) 
 
1.8 (NA) 
6.1 (1.4 – 8.5) 
TTP, months (95%CI) 4.7 (4.0 – 6.0)  2.1 (1.9 – 2.5) 
Median times to first worsening of 
QoL domains, days (95%CI) 
Global Health Status 
Physical Functioning 
Fatigue 
Emotional Functioning 
Pain 
 
 
114 (71 – 143) 
174 (123 – 288) 
113 (71 – 169) 
190 (145 – 361) 
147 (89 –NE) 
 
 
85 (37 – 140) 
60 (57 – 113) 
124 (64 – 235) 
124 (64 – 235) 
113 (58 – NE)  
Effect 
estimate 
per 
comparison 
Comparison groups  POM + DEX vs. HiDEX 
PFS – September 2012 (IRAC) HR 0.45 
95%CI 0.35 – 0.59 
P value  <0.0001 
PFS – March 2013 HR 0.48 
95%CI 0.39 – 0.60 
P value  <0.0001 
OS – September 2012 HR 0.53 
95%CI 0.37 – 0.74 
P value 0.0002 
OS – March 2013 HR 0.74 
95%CI 0.56 – 0.97 
P value 0.028 
ORR – March 2013 Odds ratio 4.22 
95%CI 2.35 – 7.58 
P value <0.0001 
DOR HR 0.52 
95%CI 0.25 – 1.05 
P value  0.0631 
TTP  HR 0.46 
95%CI 0.36 – 0.59 
P value  <0.0001 
Time to QoL worsening:  
Global Health Status 
Physical functioning 
Fatigue 
Emotional functioning 
Pain 
 
P value 
P value  
P value  
P value  
P value  
 
0.058 
0.088 
0.038 
0.023 
0.203 
 
Abbreviations: CI = confidence interval, EBMT = European Group for Blood and Bone Marrow Transplant, ECOG PS = 
Eastern Cooperative Oncology Group Performance Status, EORTC = European Organisation for Research and Treatment of 
Cancer, HiDEX = high dose dexamethasone, HR = hazard ratio, IMWG = International Myeloma Working Group Uniform 
Response criteria, IRAC = Independent Review Adjudication Committee, MR = minor response, n = Number, NA = not 
available, NE = not evaluable, NR = not reached, PR = partial response, QoL = quality of life, sCR = stringent complete re-
sponse, VGPR = very good partial response, SD = stable disease, yrs = years  
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Table 2: Adverse events (Total AEs ≥20%, grade 3 ≥ 5%, grade 4 ≥ 1% and all grade 5 events are displayed)  
MM-003 (March 2013 [45]) 
Grade (according  
to CTC version 4.0) 
Outcome, n (%) POM + DEX  
(n=300) 
HiDEX  
(n=150) 
Total Infections and infestations 203 (68) 79 (53) 
Anaemia  157 (52) 76 (51) 
Neutropenia 152 (51) 31 (21) 
Fatigue 103 (34) 41 (27) 
Thrombocytopenia 90 (30) 44 (29) 
Pyrexia 80 (27) 34 (23) 
Diarrhoea  66 (22) 28 (19) 
Constipation 65 (22) 22 (15) 
Cough  61 (20) 15 (10) 
Back pain 59 (20) 24 (16) 
Dyspnoea 59 (20) 21 (14) 
Grade 3  Infections and infestations 72 (24) 28 (19) 
Anaemia  93 (31) 48 (32) 
Neutropenia 77 (26) 13 (9) 
Fatigue 16 (5) 9 (6) 
Thrombocytopenia 27 (9) 13 (9) 
Dyspnoea 13 (4) 7 (5) 
Bone pain 20 (7) 7 (5) 
Pneumonia 30 (10) 10 (7) 
Leukopenia  20 (7) 2 (1) 
Grade 4 Infections and infestations 19 (6) 8 (5) 
Anaemia 6 (2) 7 (5) 
Neutropenia 66 (22) 11 (7) 
Thrombocytopenia 40 (13) 26 (17) 
Pneumonia 8 (3) 2 (1) 
Leukopenia 6 (2) 3 (2) 
Febrile neutropenia 5 (2) - 
Hypercalcaemia 7 (2) 2 (1) 
Grade 5 Infections and infestations 11 (4) 13 (9) 
Pneumonia 4 (1) 3 (2) 
Others Venous thromboembolism grade 3 - 4 3 (1) 0 
Treatment-related deaths  11 (4) 7 (5) 
Discontinuation due to AEs 9 10 
 
Abbreviations: CTC = Common Terminology Criteria, n = number  
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The MM-003 trial, a phase III study, compared pomalidomide + low dose 
dexamethasone (POM+DEX) to high-dose dexamethasone (HiDEX) in 
overall 455 patients (302 in the POM-DEX and 153 in the HiDEX arm) with 
either refractory or relapsed and refractory disease [45]. All patients had re-
ceived at least 2 lines of prior anti-myeloma therapy, at least 2 consecutive 
cycles of bortezomib and lenalidomide therapy, alone or in combination and 
had failed treatment with bortezomib or lenalidomide. Median age was 64 
years and the majority of patients had ECOG PS ≤1. More than 90% in each 
group were refractory to lenalidomide, 79% in each group to bortezomib and 
>70% to both lenalidomide and bortezomib, respectively.  
The final analysis for PFS, the primary outcome, was conducted in Septem-
ber 2012, followed by an updated analysis for PFS and the final analysis for 
OS in March 2013. In the publication, PFS was assessed by the investigators 
but EMA’s summary of product characteristics also provides results assessed 
by an Independent Review Adjudication Committee [49]. PFS consistently 
favoured the POM+DEX group (e.g. March 2013, investigator assessed PFS: 
POM + DEX 4.0 months vs. HiDEX 1.9 months, HR 0.48, p<0.0001). Im-
proved OS outcomes were also found in an interim analysis with a median 
follow-up of 4.2 months (HR=0.54; p<0.001) and were repeated in March 
2013 although to a lesser extent (HR 0.74, p= 0.028). This result is influ-
enced by the fact that, based on the interim analysis, the independent data 
monitoring committee recommended allowing patients from the HiDEX 
arm to cross-over to the pomalidomide arm. Consequently, 50% of patients 
in the HiDEX arm (76 individuals) received POM. ORR was observed in 
31% of patients in the POM +DEX arm in comparison to 10% in the 
HiDEX arm, yielding a statistically significant difference. Preliminary re-
sults for QoL, measured as time to worsening of QoL symptoms, were pre-
sented in one abstract [43] indicating improvements in most domains for the 
pomalidomide group.  
Concerning any grade adverse events (AEs), the most common were infec-
tions (POM+DEX 68% vs. HiDEX 53%), anaemia (POM+DEX 52% vs. 
HiDEX 51%) and neutropenia (POM+DEX 51% vs. HiDEX 21%). These 
AEs were also the most frequently observed higher grade AEs. For thrombo-
prophylaxis, thromboembolism of any grade was noted in 2% in the poma-
lidomide group and 1% in the comparator group. Supportive therapies such 
as granulocyte colony-stimulating factor were administered to 43% in the 
pomalidomide arm and 13% in the dexamethasone arm. Red blood cell 
transfusions were indicated in 20% and 21%, respectively, and platelet 
transfusion in 20% and 21%. Therapy was discontinued due to AEs in 9% in 
the POM+DEX arm and 10% in the HiDEX arm [42]. Four patients (2 sol-
id cancers, 2 skin cancers) in the pomalidomide and 1 (skin cancer) in the 
dexamethasone group developed a second primary malignancy.  
In several PFS subgroup analyses, including patients refractory to lenalido-
mide only (HR 0.50; 95%CI 0.40 – 0.62) or also to bortezomib (HR 0.52; 
95%CI 0.41 – 0.68), and for patients with either of these agents as last line 
therapy, the pomalidomide arm yielded better results. Furthermore, patients 
with high-risk cytogenetics del(17p13) and t(4p16/14q32) were analysed and 
improved outcomes for the pomalidomide group were found too (HR 0.46; 
95%CI 0.30 – 0.72). Concerning subgroup analyses for OS, improved results 
were found for patients refractory to lenalidomide (HR 0.73; 9%CI 0.55 – 
0.96) and for patients with lenalidomide as their last therapy. However, OS 
results may have been influenced by cross-over. 
MM-003 trial: 
pomalidomide + low 
dose dexamethasone  
to high-dose 
dexamethasone in  
majority of patients 
refractory to 
lenalidomide, 
bortezomib  
median PFS + 1.8 
months for 
pomalidomide group 
also improved results 
for OS, therefore cross-
over allowed 
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dexamethasone 
 
indications of 
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infections, anaemia, 
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4 second primary 
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6.1.2 Pivotal study (FDA) - MM-002 
Table 3: Summary of efficacy 
Study title  
Randomized, open label phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose 
dexamethasone (LoDex) in patients with relapsed and refractory multiple myeloma who have received 
prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): phase 2 results [29] 
Source of 
information 
FDA medical review [28], abstracts [29-37] 
Study  
identifier 
NCT00833833, CC-4047-MM-002 
Design Multi-centre, randomized (1:1 ratio), open-label, dose escalation trial (phase I), cross-
over design (phase II) 
Stratification by age (≤75 years, >75 years; prior number of treatments (2 vs. >2); prior 
thalidomide exposure (yes vs. no) 
Duration  Enrolment: NA 
Median follow-up: NA 
Cut-off date for interim analysis: 1 April 2011 
Hypothesis Superiority  
The boundary for declaring the superiority of Arm A over Arm B was based on an 
alpha-spending function of the O’Brien-Fleming type with overall α = 0.025, one-tailed. 
Funding NA 
Treatment 
groups 
Overall study 
population 
N= 221 
Intervention 
(n=113) 
Oral pomalidomide 4 mg once per day, days 1–21 of each 28-day 
treatment cycle 
+  
Dexamethasone 40 mg once per day on days 1, 8, 15 and 22 of 
each 28-day cycle for patients ≤ 75 years, and 20 mg for patients 
>75 years 
Control 
(n=108) 
Oral pomalidomide 4 mg/d, days 1–21 of each 28-day treatment 
cycle 
Endpoints 
and 
definitions 
Progression-free 
survival 
(primary outcome) 
PFS Time from randomization to the first documentation of 
disease progression or death from any cause during the 
study, whichever occurs earlier (response assessed by 
Independent Response Adjudication Committee (IRAC) 
according to EBMT criteria) 
Overall response 
rate 
ORR Partial response (PR) or better which is maintained for 
at least 6 weeks according to EBMT response criteria 
Duration of 
response 
DOR Time from the first PR or CR to the first documentation 
of progressive disease 
Overall survival OS Time from randomization to death from any cause 
Time to response TTR Time to response was defined as the time from 
randomization to the first documentation of response 
(either PR or CR) 
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Results and analysis 
Analysis  
description 
Intention-to-treat analysis 
For time to event analyses, the Kaplan-Meier method was used to estimate the 
distribution functions for each treatment arm.  
For comparison of treatment arms, the log rank test was used (two-sided, alpha 
=0.05). The trial had an 85% power to detect a 40% reduction in PFS or OS (median 
PFS of 6 and 10 months in the pomalidomide (monotherapy) arm vs. the pomalidomide 
+ dexamethasone (combination) arm).  
Planned accrual was 192 and the actual accrual was 221 patients (113 to the combination 
arm and 108 to the monotherapy arm). The planned final analysis was at 129 events, 
and the final analysis was conducted at 167 events. 
Analysis  
population 
Inclusion  Diagnosis of MM and relapsed (=after having achieved at least 
stable disease for at least 1 cycle of treatment to at least one 
prior regimen and then developed progressive disease) and 
refractory disease 
 ≥2 prior regimens, including ≥2 cycles of lenalidomide and ≥2 
bortezomib separately or in combination  
 Disease progression during or within 60 days (measured from 
the end of the last cycle) of completing treatment with the last 
treatment prior to study entry 
 ECOG PS 0-2 
Exclusion  Any of the following laboratory abnormalities: 
 ANC <1,000/μL 
 Platelet count <75,000/μL for subjects in whom <50% 
of BM nucleated cells were plasma cells; or a platelet 
count <30,000/μL for subjects in whom ≥50% of BM 
nucleated cells were plasma cells 
 Serum creatinine >3.0 mg/dL 
 Serum asparate transaminase or alanine 
aminotransaminase >3.0 x upper limit of normal  
 Serum total bilirubin >2.0 mg/dL.  
 Prior malignancies, other than MM, unless the subject had been 
free of disease for ≥3 years 
 Peripheral neuropathy ≥grade 2 
Analysis  
population 
Characteristics  POM + DEX POM 
 Age, mean (SD) 
≤75 years, % 
>75 years, % 
64.4 (9.24) 
87.6 
12.4 
62.9 (10.35) 
88.0 
12.0 
Sex, % 
Male 
Female 
 
54.9 
45.1 
 
52.8 
47.2 
Baseline MM Stage, 
% 
I 
II 
III 
 
 
7.1 
25.7 
67.3 
 
 
7.4 
26.9 
65.7 
ECOG, % 
0 
1 
2 
 
28.3 
60.2 
11.5 
 
22.2 
65.7 
10.2 
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3 0 1.9 
Number of prior 
MM therapy, 
median (min, max) 
5.0 (2.0 – 13.0) 5.0 (2.0 – 12.0) 
Prior IMiD, % 
Lenalidomide 
Thalidomide 
 
100 
68.1 
 
100 
66.7 
Prior bortezomib, % 100 100 
Prior autologous 
stem cell transplant, 
% 
74.3 75.9 
Prior 
corticosteroids, % 
100 100 
Prior alkylators, % 92.9 95.4 
Prior anthracycline, 
% 
48.7  50.0 
Refractory to, %  
lenalidomide 
bortezomib 
lenalidomide and 
bortezomib 
 
77.0 
72.6 
61.1 
 
78.7 
69.4 
59.3 
Descriptive 
statistics 
and 
estimated 
variability 
 
Treatment group POM + DEX POM 
Number of subjects N = 113 N = 108 
Median PFS, months 
(95%CI)  
 
3.8 
(3.2 – 4.9) 
 2.5 
(1.9 – 3.7) 
ORR - overall response rate 
(CR + PR), n (%) 
CR 
PR 
 
33 (29.2) 
1 (0.9) 
32 (28.3) 
 
8 (7.4) 
0 (0) 
8 (7.4) 
ORR – subgroup results 
Refractory to lenalidomide 
Yes 
No 
 
 
25.3 
42.3 
 
 
7.1 
 10.0 
Refractory to bortezomib 
Yes 
No 
 
28.0 
32.3 
 
8.0 
6.7 
Refractory to both 
lenalidomide and 
bortezomib 
Yes 
No 
 
 
27.5 
31.8 
 
 
6.3 
10.0 
Median DOR, months 
(95%CI) 
7.4 (5.1 – 9.2) NE (NE – NE) 
Median OS, months 
(95%CI) 
14.4 (12.3 – NE)  13.6 (9.6 – NE) 
Median time to response, 
months (range)  
1.9 (0.9 – 10.4) 2.0 (1.0 – 11.4) 
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Effect 
estimate per 
comparison 
Comparison groups NA 
 
Abbreviations: ANC = absolute neutrophil count, CI = confidence interval, CR = complete response, d = day, dL = decilitre, 
DOR = duration of response, EBMT  = European Group for Blood and Bone Marrow Transplant, ECOG PS = Eastern Cooper-
ative Oncology Group Performance Status, IMiD = immunomodulatory drug, IRAC = Independent Response Adjudication Com-
mittee, μL = microlitre, mg = milligramme, NA = not available,  NE = not evaluable, n = number, ORR = overall response 
rate, OS = overall survival, PFS = progression free survival, PR = partial response, SD = standard deviation, TTR = time to re-
sponse  
Table 4: Treatment-emergent adverse events (Grade 3 or 4: occurring in ≥10% of patients; serious TEAEs: occurring 
in ≥5% of patients) 
CC-4047-MM-002 
Grade  (according  
to NCI CTCAE version 3.0) Outcome, n (%) 
POM + DEX 
(n=112) 
POM  
(n=107) 
Grade 3 or 4 
 
Any 99 (88) 96 (90) 
Neutropenia 43 (38) 50 (47) 
Anaemia 23 (21) 24 (22) 
Thrombocytopenia 21 (19) 24 (22) 
Leukopenia 11 (10) 6 (6) 
Asthenia and fatigue 14 (13) 12 (11) 
Pneumonia 24 (21) 16 (15) 
Back pain 10 (9) 11 (10) 
Dyspnoea  14 (13) 7 (7) 
Serious  Any SAE 69 (62) 72 (67) 
Febrile neutropenia 1 (1) 5 (5) 
Pyrexia 5 (5) 3 (3) 
Pneumonia 24 (21) 17 (16) 
Sepsis  3 (3) 6 (6) 
Urinary tract infections 6 (5) 0 (0) 
Dehydration 3 (3) 5 (5) 
Hypercalcaemia 3 (3) 5 (5) 
Back pain and bone pain 3 (3) 5 (5) 
Renal failure  7 (6) 10 (9) 
Dyspnoea & Hypoxia 7 (6) 5 (5) 
Abbreviations: CTCEA = Common Terminology Criteria for Adverse Event, NCI = National Cancer Institute, n = number, 
SAE = serious adverse event, TEAE = treatment-emergent adverse events, 
 
The CC-4047-MM-002 was a phase I/II trial. Phase I of the trial comprised 
38 patients (results are not displayed) [50] and phase II comprised overall 
221 patients with relapsed and refractory MM. Inclusion criteria were ≥2 
prior therapies and ≥2 cycles of therapy including lendalidomide and borte-
zomib (either separately or in combination) for MM. In addition, patients 
had to have refractory disease, defined as documented progressive disease 
≤60 days after completing their last myeloma therapy.  
MM-002 trial phase I/II 
pivotal study 
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In Phase II, 113 patients were randomised to receive pomalidomide + dex-
amethasone (POM + DEX) and 108 individuals to pomalidomide only 
(POM). The majority of patients enrolled were ≤75 years, had an ECOG sta-
tus of 0 or 1 and stage III MM. Median number of prior therapies was 5 in 
both groups. All patients had received prior corticosteroids, lenalidomide, 
and bortezomib. Concerning the latter, 78% were refractory to lenalidomide, 
71% to bortezomib and 60% to both agents.  Patients with confirmed pro-
gressive disease were allowed to cross-over from the POM arm to the combi-
nation arm and 61 patients did. 
The median treatment duration was 21.6 weeks. In the combination arm, 
median exposure was 21.8 weeks compared to 20.6 weeks in the POM only 
arm. Overall, the median number of cycles received was similar between the 
two groups (5.0 cycles) but, prior to cross-over of patients in the POM only 
arm, the median number of cycles was only 2.0. Dose-reductions were neces-
sary in 39% of patients in the POM+DEX arm and in 17% in the POM only 
arm, and dose interruptions occurred in 64% in the combination arm and in 
59% in the POM only arm.  
Median PFS, assessed by an Independent Response Adjudication Commit-
tee, was the primary outcome and was 3.8 months in the POM-DEX arm and 
2.5 in the POM only arm. Overall response rates were 29% in the combina-
tion arm and 7% in the single-agent arm. Since only 1 complete response 
was observed in the POM+DEX arm, the majority were partial responses. 
The median duration of response was only evaluable in the POM+DEX 
arm, where it was 7.4 months. The difference in median overall survival was 
0.8 months, favouring the combination arm.  
Several subgroup analyses were planed prior to the study start including 
subgroups based on gender, age group, number of prior anti-myeloma ther-
apies and prior thalidomide exposure. In addition, several post-hoc analyses 
were conducted [30-35], including patients previously treated with carfil-
zomib and refractory status to lenalidomide, bortezomib or both. Objective 
response rates for patients refractory to lenalidomide, bortezomib or both 
were 25%, 28% and 28%, respectively, in the POM + DEX arm and 7%, 8% 
and 6% in the POM only arm. In comparison, the rates for non-refractory 
patients were 42%, 32% and 32% in the POM+DEX arm and 10%, 7% and 
10% in the POM-only arm, respectively. 
Concerning adverse events (AEs), treatment-emergent AEs of grade 3 or 4 
were very frequently observed in both groups (88% in the POM+DEX arm, 
90% in the POM only arm). The most common were disorders associated 
with the blood and lymphatic system, i.e. anaemia and neutropenia.  Infec-
tions, foremost among them pneumonia of grade 3 or 4 were seen in 21% 
(POM+DEX) and 15% (POM) of patients. More than 60% in each group 
experienced serious AEs (e.g. life-threatening AEs requiring hospitalisa-
tion). The most common serious AEs were infections, mainly pneumonia.   
Overall, 41 patients died of which the majority, i.e. 23 patients, were due to 
disease progression. Deaths due to treatment-related adverse events were the 
second most common cause of death. In the POM+DEX group 6 deaths 
(5.3%) were attributable to treatment, mainly because of infections (4 pa-
tients) and cerebral or subarachnoid haemorrhage (2 patients). Seven deaths 
(6.5%) occurred in patients in the single-agent group (6 infection-related, 1 
caused by cerebral or subarachnoid haemorrhage).  
 
221 patients with 
relapsed and refractory 
MM treated with 
pomalidomide + low 
dose dexamethasone or 
with pomalidomide only 
median PFS: 3.8 months 
in combination arm and 
2.5 months in 
pomalidomide only arm; 
difference in OS 0.8 
months 
several subgroup 
analyses 
 
ORR 25% – 28% 
grade 3 or 4 AE in about 
90% 
most common: 
anaemia, neutropenia 
5% – 6% died due to 
treatment  
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6.1.3 Further studies 
The IFM 2009-02 trial, a supportive study,  was a randomised phase II study 
testing two different pomalidomide regimens [27, 28]. Forty-three patients 
received 4 mg pomalidomide on days 1–21 of a 28-day cycle in addition to 40 
mg dexamethasone (21/28 group), whereas 41 patients received 4 mg poma-
lidomide on days 1–28 of a 28-day cycle in addition to 40 mg dexamethasone 
(28/28 group).  Patients had to have relapsed and refractory MM after at 
least one prior MM therapy and progressive disease after bortezomib and/or 
lenalidomide treatment. Furthermore, patients had to have received at least 
two cycles of lenalidomide and bortezomib.  
The study population had a median age of 60 years, 31% were ≥65 years and 
the vast majority had an ECOG performance status of 0 or 1. The median 
number of prior MM therapies was 5 and, as stated in the inclusion criteria, 
all had received prior lenalidomide, bortezomib and glucocorticoids. Over-
all, 89% were refractory to lenalidomide, 81% to bortezomib and 76% to 
both agents. ORR 34% – 35%, median PFS 3.7 – 5.4 months. 
At median follow-up of 22.8 months, ORR, the primary outcome, was 35% in 
the 21/28 group and 34% in the 28/28 group. Of these, the main response 
was PR (27% overall). The median time to first response was 2.7 months and 
1.1 months in the 21/28 group and the 28/28 group, respectively. Corre-
sponding numbers for median duration of response were 6.4 months and 8.3 
months. Patients receiving pomalidomide on 21 days of a 28-day cycle had a 
median PFS of 5.4 months, and those receiving pomalidomide on all 28 days 
of the cycle had a PFS of 3.7 months. OS was the same in both groups (14.9 
and 14.8 months, respectively). 
Results for ORR, PFS and OS were also presented for subgroups of the 
whole study population. ORR, PFS and OS were 31%, 3.8 months and 13.8 
months, respectively, for patients refractory to lendalidomide and borte-
zomib. Less favourable outcomes were observed for individuals who had re-
ceived more than 6 lines of therapy prior to enrolment in the IFM-2009-02 
trial (ORR: 21%, PFS: 3.2 months, OS: 9.2 months) and in patients with 
poor cytogenetic abnormalities that is del(17p) and t(4;14) (ORR: 27%, PFS: 
2.6 months, OS: 5.4 months).  
Grade 3 or 4 AEs occurred in 91% (21/28 group) and 83% (28/28 group). 
The majority of AEs concerned those arising due to myelosuppression such 
as anaemia, neutropenia and thrombocytopenia. About 74% in each group 
experienced serious treatment-emergent AEs. The most common was pneu-
monia (30% in the 21/28 group and 24% in the 28/28 group). The median 
number of cycles received was 8 in the 21/28 group and 6 in the 28/28 group. 
Discontinuation due to AEs occurred overall in 2% (2 patients), both of 
which were in the 28-day cycle group. Three patients (7%) died in each 
group due to treatment-emergent AEs. Causes of death were pneumonia (2 
patients each), and 1 patient each died due to cerebrovascular haemorrhage 
and renal failure.  
 
 
randomised phase II trial  
comparing  
2 different 
pomalidomide regimens 
+ dexamethasone 
patients were previously 
treated with 
bortezomib/lenalidomide 
majority refractory to 
lenalidomide, 
bortezomib or both 
subgroup results 
including patients 
refractory to 
lenalidomide and 
bortezomib, with poor 
cytogenetic 
abnormalities 
grade 3 or 4 AEs in 83%-
91%, mainly due to 
myelosuppression 
 
serious-treatment 
emergent AEs: 
pneumonia 
7% died in each group 
due  
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Lacy et al. [46] investigated pomalidomide in a sequential phase II study at 
doses of 2 mg and 4 mg pomalidomide every day of a 28-day cycle in addi-
tion to 40 mg dexamethasone weekly. Enrolled patients had to have been 
treated previously and be refractory to lenalidomide and bortezomib. Over-
all, 70 patients were included in the study, 35 in each group. The study pop-
ulation consisted mainly of men (≥60%) with a good performance status 
and a median age ranging between 61 and 62 years. In the 2 mg group all pa-
tients had received ≥3 prior chemotherapies and in the 4 mg group ≥94% of 
patients. ORR, the primary outcome, was 26% in the 2 mg group and 28% in 
the 4 mg group, while PFS was 6.5 months and 3.2 months, respectively. At 6 
months, the OS rate was 78% and 67%, respectively. AEs were comparable 
to those already described in chapter 6.1, since myelosuppression was the 
most frequent occurrence. Grade 3 or 4 neutropenia was the most common 
(2 mg: 51%; 4 mg: 65%) followed by leukopenia (2 mg: 40%; 4 mg: 62%). 
Despite the fact that 31% of patients experienced pneumonia in the 2 mg 
cohort, only 9% were considered to be treatment related. In the 2 mg group, 
80% experienced neuropathy in comparison to 89% in the 4 mg group, but 
nearly all cases were of grade 1 or 2.  
 
 
7 Estimated costs 
No costs estimates are available yet for Austria.  
 
 
8 Ongoing research 
Besides the still ongoing MM-003 trial, 3 further phase III studies were iden-
tified on clinicaltrials.gov and on clinicaltrialsregister.eu:  
NCT01734928 (OPTIMISMM, MM-007): compares the efficacy of the com-
bination of pomalidomide, bortezomib and dexamethasone to the combina-
tion of bortezomib and dexamethasone in patients with relapsed/refractory 
multiple myeloma. This study will also assess how safe the combination of 
pomalidomide, bortezomib and dexamethasone is compared to the combina-
tion of bortezomib and dexamethasone. The estimated study completion 
date is January 2015. 
NCT01324947 (NIMBUS, MM-003/C): evaluates the efficacy and safety of 
pomalidomide monotherapy in subjects with refractory or relapsed and re-
fractory multiple myeloma who were enrolled in study CC-4047-MM-003 
and discontinued treatment with high-dose dexamethasone due to disease 
progression. The estimated study completion date is September 2013.  
NCT01712789 (STRATUS, MM-010): the primary purpose of the study is to 
evaluate the safety and efficacy of and generate pharmacokinetic and bi-
omarker data for the combination of pomalidomide and low-dose dexame-
thasone in patients with refractory or relapsed and refractory multiple mye-
loma. The estimated study completion date is November 2019. 
another phase II study 
compared 2 mg and 4 
mg pomalidomide + 
dexamethasone in 
overall 70 patients 
 
AEs comparable to 
those reported in 
previous studies 
no cost estimates 
available 
3 further ongoing phase 
III trials 
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Furthermore, the drug is in phase III for the treatment of myelofibrosis. 
Moreover, its use for the treatment of several other diseases such as prostate 
cancer, Waldenstrom's macroglobulinaemia and primary systemic amyloido-
sis is currently being investigated.   
 
9 Commentary 
Pomalidomide was approved by the FDA in February 2013 and by the EMA 
in August 2013. The licensed indication is for the treatment of adult patients 
who have received at least two prior treatment regimens, including both le-
nalidomide and bortezomib, and have demonstrated disease progression on 
the last therapy.  
The FDA’s decision was based on the efficacy outcomes of two phase II stud-
ies, the pivotal MM-002 trial (221 patients) and one supportive study, the 
IFM-2009-02 trial (84 patients). The MM-002 trial compared pomalidomide 
with and without 40 mg dexamethasone weekly and the IFM 2009-02 trial 
compared pomalidomide either continuously or for 21 days within a 28 days 
cycle in addition to 40 mg dexamethasone weekly. Patients were heavily pre-
treated (a median of 5 prior therapies) and included patients refractory to 
lenalidomide, bortezomib or both. In the MM-002 trial >70% of patients 
were refractory to either of the drugs and about 60% to both. These numbers 
were considerably lower in the IFM-2009-02 trial. ORR in these trials 
ranged between 29% and 35%, PFS from 3.8 to 5.4 months, OS from 14.4 to 
14.9 months and DOR was 6.4 and 7.4 months, respectively.  
The FDA acknowledged that, based on the available evidence, isolation of 
the treatment effect of pomalidomide is not possible since pomalidomide 
was part of the therapy in both arms. Further the safety population was with 
overall 303 patients small [28]. However, the drug was approved under the 
accelerated approval regulations in the U.S., highlighting the need for ther-
apeutic options for heavily pre-treated patients who have relapsed and re-
fractory MM despite established therapies such as bortezomib and lenalid-
omide [51]. In order to support the results of the phase II studies and ulti-
mately to gain regular approval, the applicant mentioned two confirmatory 
randomised controlled trials [52]: the MM-003 and the MM-007 trial 
(NCT01734928). The latter will evaluate the addition of pomalidomide to 
bortezomib and dexamethasone but study results will not be available prior 
to January 2015, the final data collection date for the primary outcome 
measure [41].  
The EMA has recently granted market authorisation based on the results of 
the MM-003 trial, which had enrolled patients with similar characteristics as 
the two phase II trials, i.e. heavily pre-treated patients and refractory disease 
[45]. Pomalidomide + low dose dexamethasone was compared with high-
dose dexamethasone in overall 455 patients, yielding statistically significant 
improved outcomes for patients in the combination arm. The difference in 
median PFS was 2.1 months and in OS 4.6 months after 10 months of follow-
up, favouring the pomalidomide arm. Preliminary outcomes concerning 
quality-of-life were also presented, indicating improved results for pomalid-
omide [43]. Nonetheless, the open-label design of the study may influence 
these results.  
also under investigation 
for other diseases such 
as prostate cancer, 
myelofibrosis, 
amyloidosis 
approved in the U.S. in 
February 2013  
and by EMA in August 
2013 
2 phase II trials (MM-
002, IFM-2009-02) 
served as the basis for 
the FDA’s decision 
even though these trials 
do not allow isolation of 
treatment effect, 
approval in the U.S 
under accelerated 
approval regulation 
 
high unmet medical 
need in heavily pre-
treated patients with 
relapsed and refractory 
disease  
phase III study (MM-
003) trial available, 
indicating gains in PFS, 
OS, QoL for patients 
treated with 
pomalidomide + low-
dose dexamethasone in 
comparison to high-dose 
dexamethasone  
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In terms of safety, at least one grade 3 or 4 AE was experienced by about 
90% of patients in the phase II studies, the majority being due to myelosup-
pression, e.g. neutropenia (38%–63%) and anaemia (21%–33%). Serious AEs 
occurred in 62%–74%. In the phase III trial, grade ≥3 neutropenia was ob-
served in 48% of the pomalidomide group and 16% of the high-dose dexa-
methasone group, and infections occurred in 30% and 24%, respectively. 
Comparable rates were found in the two groups for thrombocytopenia (22% 
vs. 26%). Due to the high embryo-foetal risk of pomalidomide, it is only 
available under a risk evaluation and mitigation strategy programme in the 
US. Thrombo-embolic AEs, a side-effect associated with pomalidomide, 
were rare with thrombo-prophylaxis (1%–2%). Secondary primary malig-
nancies occurred in the MM-003 trial in 4 patients (1.3%) in the pomalido-
mide arm in comparison to 1 patient (0.7%) in the dexamethasone arm.  
Therapy for MM is currently undergoing substantial changes, raising ques-
tions as to the optimal sequences and combination of regimens.  For exam-
ple, pomalidomide is being tested in combination with a proteasome inhibi-
tor. i.e. bortezomib, and several other drugs are in development, including 
monoclonal antibodies (e.g elotuzumab, lucatumumab, dacetuzumab, dara-
tumumab) and deubiquitylating agents (ixazomib)) [53]. Further, since the 
first remission [51] usually has the longest duration and yields the best clin-
ical outcomes for patients, the most effective therapies should be used in the 
front-line setting [51]. Besides direct comparisons of agents available, the ef-
ficacies of new agents in earlier stages of treatment are therefore of interest.  
In addition, further characterisation of patients with the highest potential to 
benefit from pomalidomide may be helpful in determining the best treat-
ment strategy. The MM-003 trial conducted subgroup analyses including pa-
tients refractory to bortezomib and lenalidomide, efficacy with regards to 
the last line of therapy and patients with high-risk cytogenetics. Despite 
conflicting evidence as to the impact of prior therapies on the efficacy of fur-
ther lines of treatment, there are some indications that patients with thalid-
omide-refractory disease may be associated with poorer outcomes than those 
refractory to bortezomib or lenalidomide [51], but no information for pa-
tients refractory to thalidomide is available.  
In the future, development of predictive biomarkers for selecting the opti-
mal therapy and predicting responses to immune-modulatory drugs could 
also help guide treatment decisions [5, 21]. Safety data for larger patient 
groups and with a longer follow-up are also important to better describe the 
risks associated with pomalidomide. 
Heavily pre-treated MM patients remain a difficult to treat group. Especial-
ly for patients who are refractory to established therapies such as lenalido-
mide or bortezomib [51], prognosis is poor with a median OS of about 9 
months and a PFS of 5 months [21]. Since no standard therapy for this set-
ting exists [21], agents such as pomalidomide would therefore clearly ad-
dress an unmet medical need. The first positive results of studies on poma-
lidomide suggest that relapsed and refractory patients benefit from this 
therapy. In addition, the oral application also provides a benefit for patients, 
for example in comparison to carfilzomib, a drug for injection currently li-
censed only the U.S.  
 
 
AEs of grade 3 or 4 very 
common, serious AEs in 
62%-74%, mainly due 
to myelosuppression 
 
high embryo-fetal risk, 
thrombo-prophylaxis 
indicated 
substantial changes in 
MM therapy 
several new drugs 
available 
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of patients with highest 
potential to benefit 
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new treatment options 
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